Renalytix plc American Depositary Shares Stock Price, News & Analysis

RenalytixAI has entered an exclusive option agreement with Joslin Diabetes Center to access novel biomarkers for kidney disease to enhance its KidneyIntelX platform. These biomarkers aim to improve early disease identification and therapeutic response understanding. Clinical validation studies are set to begin in the second half of 2021. RenalytixAI's ongoing collaboration with Joslin aims to leverage advanced research to enhance kidney disease management globally.

Renalytix AI shares findings from a 401 physician study presented at the National Kidney Foundation's 2021 Spring Clinical Meetings, emphasizing the utility of KidneyIntelX in assessing diabetic kidney disease risk. Results indicate that 98% of primary care physicians would order the test if reimbursement was secured, with significant increases in prescribing appropriate medications and referrals to specialists when utilizing KidneyIntelX. This data underscores the potential for better patient outcomes and reduced healthcare costs through early intervention.

RenalytixAI plc (NASDAQ: RNLX) announced significant findings regarding its KidneyIntelX™ platform, published in Diabetologia. The study, involving 1,146 type 2 diabetes patients, demonstrated that KidneyIntelX outperforms the standard care in predicting kidney function decline and kidney failure. It effectively segmented patients into high, intermediate, and low-risk categories, achieving a 69% positive predictive value for high-risk patients, compared to 40% from existing models. This advancement is expected to optimize clinical care and reduce costs associated with kidney disease.

Renalytix AI plc (NASDAQ: RNLX) has announced updates on the Medicare Coverage of Innovative Technology (MCIT) pathway, which will provide coverage for innovative medical devices and diagnostics. The Centers for Medicare & Medicaid Services (CMS) has delayed the MCIT rule's implementation by 60 days, initiating a 30-day comment period. RenalytixAI asserts that the MCIT rule will likely be effective during the FDA review of its product, KidneyIntelX, and that the delay will not materially impact its business plan.

Renalytix AI plc (NASDAQ: RNLX) announced the issuance of 17,652 ordinary shares under its Employee Share Purchase Plan (ESPP) to settle the purchase of 8,826 American Depositary Shares (ADSs) by employees. CFO O. James Sterling acquired 4,596 ordinary shares at £4.50 each ($12.563 per ADS). Following the issuance, the total number of ordinary shares will be 72,047,286, with each share carrying one vote. Admission of the new shares on the London Stock Exchange is expected on or around March 9, 2021.

Renalytix AI plc (NASDAQ: RNLX) reported its financial results for the quarter and six months ended December 31, 2020. The company recognized $0.4 million in pharmaceutical services revenue, with an operating loss of $8.9 million, compared to $4.7 million a year prior. Significant partnerships with DaVita and the University of Utah aim to enhance access to KidneyIntelX, while the recent finalization of the Medicare Coverage of Innovative Technology rule paves the way for broader insurance coverage. Cash reserves increased substantially to $74.5 million.

Renalytix AI (NASDAQ: RNLX) and the University of Utah have partnered to enhance kidney health management through the implementation of the KidneyIntelX diagnostic platform. This initiative aims to identify early-stage chronic kidney disease (CKD) patients and reduce kidney failure risks in large populations. The partnership includes integrating KidneyIntelX into electronic health records for over 1,700 clinicians, optimizing patient care through data-driven analytics and innovative care delivery models. Financial support will facilitate ongoing research and development in kidney disease treatment.

Renalytix AI plc (NASDAQ: RNLX) has announced the upcoming release of its financial results for the six and three months ended December 31, 2020, set for March 2, 2021. A conference call featuring CEO James McCullough and CFO O. James Sterling will take place at 8:30 a.m. EST to discuss these results and provide a corporate update. The company specializes in artificial intelligence-driven in vitro diagnostics for kidney disease, which affects over 850 million people worldwide, emphasizing the urgency of improved management in clinical settings.